IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Lannett Company, Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) concerning possible violations of federal securities laws between September 12, 2013 and November 3, 2016 inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the January 17, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Lannett made false and/or misleading statements and/or failed to disclose: that the Company's drug pricing relied on unsustainable pricing methodologies; that Lannett lacked effective internal controls concerning its drug pricing methodologies; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. On November 3, 2016, Bloomberg News reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Lannett, to determine whether they unlawfully colluded with each other to fix generic drug prices.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

If you liked this article you might like

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers